TY - JOUR
T1 - Nighttime Agitation in Persons with Dementia as a Manifestation of Restless Legs Syndrome
AU - Richards, Kathy C.
AU - Allen, Richard P.
AU - Morrison, Janet
AU - Fry, Liam
AU - Kovach, Christine R.
AU - Rangel, Angelica
AU - Loera, Ana
AU - Wang, Yanyan
AU - Hanlon, Alexandra L.
AU - Lozano, Alicia J.
AU - Bliwise, Donald L.
N1 - Funding Information:
This work was supported by the National Institute on Aging ( R01 AG 051588 ; R01 AG 027778 ). Research reported in this publication was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR003015. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine
PY - 2021/7
Y1 - 2021/7
N2 - Objectives: Nighttime agitation or “sundowning” is challenging for clinicians and caregivers to manage in older adults in the dementia stage of Alzheimer's disease (AD-D). Our research previously revealed that nighttime agitation might be a manifestation of restless legs syndrome (RLS). The current study aims to describe the characteristics of older adults with AD-D, nighttime agitation, and RLS, and to evaluate sleep disturbance and iron status in relation to nighttime agitation severity. Design: An observational study with baseline descriptive and correlational data from a clinical trial. Setting and Participants: Long-term care (n = 69) and independent living (n = 7); age 82.91 ± 9.46 years, with AD-D, nighttime agitation, and RLS. Measurements: Trained observers counted nighttime agitation behaviors. Independent variables were age; cognition measured by the Mini-Mental State Examination; minutes slept from actigraphy; transferrin saturation percentage (TS%) and transferrin from fasting blood samples; and illness severity using the Cumulative Illness Rating Scale for Geriatrics. Bivariate and multivariable linear regression models were generated. Results: In the multivariable model, sleep minutes (P = .002) and TS% (P = .003) were negatively associated with frequency of nighttime agitation behaviors, and they explained 20% of the variance. Seventy-nine percent received 1 or more medications that worsen RLS symptoms, such as antihistamines and serotonin reuptake inhibitors. Conclusions and Implications: We encourage clinicians to consider nighttime agitation as a manifestation of RLS. Treatment of iron deficiency indicated by low TS% and deprescribing medications that exacerbate RLS may decrease nighttime agitation, improve sleep, and enhance quality of life in older adults with AD-D.
AB - Objectives: Nighttime agitation or “sundowning” is challenging for clinicians and caregivers to manage in older adults in the dementia stage of Alzheimer's disease (AD-D). Our research previously revealed that nighttime agitation might be a manifestation of restless legs syndrome (RLS). The current study aims to describe the characteristics of older adults with AD-D, nighttime agitation, and RLS, and to evaluate sleep disturbance and iron status in relation to nighttime agitation severity. Design: An observational study with baseline descriptive and correlational data from a clinical trial. Setting and Participants: Long-term care (n = 69) and independent living (n = 7); age 82.91 ± 9.46 years, with AD-D, nighttime agitation, and RLS. Measurements: Trained observers counted nighttime agitation behaviors. Independent variables were age; cognition measured by the Mini-Mental State Examination; minutes slept from actigraphy; transferrin saturation percentage (TS%) and transferrin from fasting blood samples; and illness severity using the Cumulative Illness Rating Scale for Geriatrics. Bivariate and multivariable linear regression models were generated. Results: In the multivariable model, sleep minutes (P = .002) and TS% (P = .003) were negatively associated with frequency of nighttime agitation behaviors, and they explained 20% of the variance. Seventy-nine percent received 1 or more medications that worsen RLS symptoms, such as antihistamines and serotonin reuptake inhibitors. Conclusions and Implications: We encourage clinicians to consider nighttime agitation as a manifestation of RLS. Treatment of iron deficiency indicated by low TS% and deprescribing medications that exacerbate RLS may decrease nighttime agitation, improve sleep, and enhance quality of life in older adults with AD-D.
KW - Alzheimer's disease
KW - Behavioral Indicators Test–Restless Legs
KW - RLS
KW - agitation
KW - sleep disorders
UR - http://www.scopus.com/inward/record.url?scp=85098848751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098848751&partnerID=8YFLogxK
U2 - 10.1016/j.jamda.2020.11.026
DO - 10.1016/j.jamda.2020.11.026
M3 - Article
C2 - 33347845
AN - SCOPUS:85098848751
SN - 1525-8610
VL - 22
SP - 1410
EP - 1414
JO - Journal of the American Medical Directors Association
JF - Journal of the American Medical Directors Association
IS - 7
ER -